目的 探讨盐酸坦洛新缓释片联合前列倍喜胶囊治疗前列腺炎的临床疗效。方法 选取2016年5月-2017年5月四川石油管理局总医院收治的前列腺炎患者64例为研究对象，将所有患者随机分为对照组和治疗组，每组各32例。对照组患者口服前列倍喜胶囊，6粒/次，3次/d。治疗组患者在对照组治疗的基础上口服盐酸坦洛新缓释片，1片/次，1次/d。两组患者均连续治疗1个月。观察两组的临床疗效，比较两组的NIH-CPSI积分、白细胞（WBC）和卵磷脂小体。结果 治疗后，对照组和治疗组的总有效率分别为78.13%、96.88%，两组比较差异有统计学意义（P<0.05）。治疗后，两组NIH-CPSI积分显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组NIH-CPSI积分明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组WBC水平显著降低，卵磷脂小体水平显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些观察指标明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 盐酸坦洛新缓释片联合前列倍喜胶囊治疗前列腺炎具有较好的临床疗效，可改善患者临床症状和相关指标，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Tamsulosin Hydrochloride Sustained Release Tablets combined with Qianliebeixi Capsules in treatment of prostatitis. Methods Patients (64 cases) with prostatitis in General Hospital of CNPC Sichuan Administration from May 2016 to May 2017 were randomly divided into control and treatment groups, and each group had 32 cases. Patients in the control group were po administered with Qianliebeixi Capsules, 6 grains/time, three times daily. Patients in the treatment group were po administered with Tamsulosin Hydrochloride Sustained Release Tablets on the basis of the control group, 1 tablet/time, once daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and NIH-CPSI scores, (white blood cell) WBC, and lecithin bodies in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.13% and 96.88%, respectively, and there was difference between two groups (P<0.05). After treatment, NIH-CPSI scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the NIH-CPSI score in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of WBC in two groups were significantly decreased, but the levels of lecithin bodies in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Tamsulosin Hydrochloride Sustained Release Tablets combined with Qianliebeixi Capsules has clinical curative effect in treatment of prostatitis, can improve clinical symptoms and related indexes, which has a certain clinical application value.